Combined use of rituximab and plasmapheresis pre-transplant increases post-transplant infections in renal transplant recipients with basiliximab induction therapy

Transplant Infectious Disease

Volumn 15, Issue 6, 2013, Pages 559-568

  Chung, B H ^a   Yun, J T ^a   Ha, S E ^a   Kim, J I ^a   Moon, I S ^a   Choi, B S ^a   Park, C W ^a   Kim, Y S ^a   Yang, C W ^a  

^a The Catholic University of Korea College of Medicine   (South Korea)

Author keywords

Infectious complication; Kidney transplantation; Plasmapheresis; Rituximab

Indexed keywords

AMPHOTERICIN B; BASILIXIMAB; CYCLOSPORIN; GANCICLOVIR; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; VORICONAZOLE;

ACUTE GRAFT REJECTION; ADULT; ANTIBODY MEDIATED REJECTION; ARTICLE; BACTERIAL ARTHRITIS; BK VIRUS INFECTION; CAUSE OF DEATH; CELLULITIS; CHOLECYSTITIS; CHRONIC GRAFT REJECTION; COLITIS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG MEGADOSE; FEMALE; FOLLOW UP; FUNGAL SINUSITIS; GRAFT INFECTION; GRAFT RECIPIENT; HERPES ZOSTER; HUMAN; HUMAN TISSUE; INFECTION FREE SURVIVAL RATE; INFECTION RISK; INFECTIOUS COMPLICATION; INFLUENZA A (H1N1); INVASIVE ASPERGILLOSIS; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; LOW DRUG DOSE; LUNG MYCOSIS; MAJOR CLINICAL STUDY; MALE; PANCYTOPENIA; PARVOVIRUS INFECTION; PERITONSILLAR ABSCESS; PLASMAPHERESIS; PNEUMONIA; POSTOPERATIVE COMPLICATION; POSTPRIMARY TUBERCULOSIS; PREVALENCE; PRIORITY JOURNAL; URINARY TRACT INFECTION; VIREMIA;

INFECTIOUS COMPLICATION; KIDNEY TRANSPLANTATION; PLASMAPHERESIS; RITUXIMAB;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BK VIRUS; COMBINED MODALITY THERAPY; CYTOMEGALOVIRUS INFECTIONS; DISEASE-FREE SURVIVAL; FEMALE; GRAFT REJECTION; HERPES ZOSTER; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INDUCTION CHEMOTHERAPY; KIDNEY TRANSPLANTATION; LUNG DISEASES, FUNGAL; MALE; MIDDLE AGED; PLASMAPHERESIS; PNEUMONIA, BACTERIAL; POLYOMAVIRUS INFECTIONS; PREOPERATIVE CARE; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TUMOR VIRUS INFECTIONS; URINARY TRACT INFECTIONS;

EID: 84888868733     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12135     Document Type: Article

References (29)

1. Marfo K, Lu A, Ling M, Akalin E. Desensitization protocols and their outcome. Clin J Am Soc Nephrol 2011; 6 (4): 922-936.
2. Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006; 6 (2): 346-351.
3. Ichimaru N, Takahara S. Japan's experience with living-donor kidney transplantation across ABO barriers. Nat Clin Pract Nephrol 2008; 4 (12): 682-692.
4. Gloor JM, Stegall MD. ABO incompatible kidney transplantation. Curr Opin Nephrol Hypertens 2007; 16 (6): 529-534.
5. Audard V, Kamar N, Sahali D, et al. Rituximab therapy prevents focal and segmental glomerulosclerosis recurrence after a second renal transplantation. Transpl Int 2012; 25 (5): e62-e66.
6. Hickson LJ, Gera M, Amer H, et al. Kidney transplantation for primary focal segmental glomerulosclerosis: outcomes and response to therapy for recurrence. Transplantation 2009; 87 (8): 1232-1239.
7. Montgomery RA, Zachary AA. Transplanting patients with a positive donor-specific crossmatch: a single center's perspective. Pediatr Transplant 2004; 8 (6): 535-542.
8. Jordan SC, Vo A, Bunnapradist S, et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 2003; 76 (4): 631-636.
9. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359 (3): 242-251.
10. Kahwaji J, Sinha A, Toyoda M, et al. Infectious complications in kidney-transplant recipients desensitized with rituximab and intravenous immunoglobulin. Clin J Am Soc Nephrol 2011; 6 (12): 2894-2900.
11. Habicht A, Broker V, Blume C, et al. Increase of infectious complications in ABO-incompatible kidney transplant recipients-a single centre experience. Nephrol Dial Transplant 2011; 26 (12): 4124-4131.
12. Vo AA, Wechsler EA, Wang J, et al. Analysis of subcutaneous (SQ) alemtuzumab induction therapy in highly sensitized patients desensitized with IVIG and rituximab. Am J Transplant 2008; 8 (1): 144-149.
13. Chung BH, Lee JY, Kang SH, et al. Comparison of clinical outcome between high and low baseline anti-ABO antibody titers in ABO-incompatible kidney transplantation. Ren Fail 2011; 33 (2): 150-158.
14. Chung BH, Kim KW, Kim BM, et al. Dysregulation of Th17 cells during the early post-transplant period in patients under calcineurin inhibitor based immunosuppression. PLoS One 2012; 7 (7): e42011.
15. Tobian AA, Shirey RS, Montgomery RA, Tisch DJ, Ness PM, King KE. Therapeutic plasma exchange reduces ABO titers to permit ABO-incompatible renal transplantation. Transfusion 2009; 49 (6): 1248-1254.
16. Chung BH, Hong YA, Kim HG, et al. Clinical usefulness of BK virus plasma quantitative PCR to prevent BK virus associated nephropathy. Transpl Int 2012; 25 (6): 687-695.
17. Scemla A, Loupy A, Candon S, et al. Incidence of infectious complications in highly sensitized renal transplant recipients treated by rituximab: a case-controlled study. Transplantation 2010; 90 (11): 1180-1184.
18. Grim SA, Pham T, Thielke J, et al. Infectious complications associated with the use of rituximab for ABO-incompatible and positive cross-match renal transplant recipients. Clin Transplant 2007; 21 (5): 628-632.
19. Pohl MA, Lan SP, Berl T. Plasmapheresis does not increase the risk for infection in immunosuppressed patients with severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. Ann Intern Med 1991; 114 (11): 924-929.
20. Daugirdas JT, Blake PG, Ing TS. Handbook of Dialysis (4th edn). Philadelphia: Lippincott Williams & Wilkins, 2006.
21. Schroder C, Azimzadeh AM, Wu G, Price JO, Atkinson JB, Pierson RN. Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys. Transpl Immunol 2003; 12 (1): 19-28.
22. Vieira CA, Agarwal A, Book BK, et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 2004; 77 (4): 542-548.
23. Spina M, Jaeger U, Sparano JA, et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Blood 2005; 105 (5): 1891-1897.
24. Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006; 355 (19): 1967-1977.
25. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 (Suppl 3): S1-S155.
26. Kamar N, Milioto O, Puissant-Lubrano B, et al. Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. Am J Transplant 2010; 10 (1): 89-98.
27. Patel R, Paya CV. Infections in solid-organ transplant recipients. Clin Microbiol Rev 1997; 10 (1): 86-124.
28. Ergin F, Arslan H, Azap A, Demirhan B, Karakayali H, Haberal M. Invasive aspergillosis in solid-organ transplantation: report of eight cases and review of the literature. Transpl Int 2003; 16 (4): 280-286.
29. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32 (3): 358-366.